Stockreport

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]

Werewolf Therapeutics, Inc.  (HOWL) 
PDF WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company p [Read more]